AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20879960 — intervention group
Group type: EXPERIMENTAL
Intervention: Matsuda Index differences between tests for IFG
Number of subjects: 78
Study 20879960 — intervention group
Group type: EXPERIMENTAL
Intervention: Matsuda Index differences between tests for diabetes
Number of subjects: 78
Study 20879960 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposition Index differences between tests for NFG
Number of subjects: 78
Study 20879960 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposition Index differences between tests for IFG
Number of subjects: 78
Study 20879960 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposition Index differences between tests for diabetes
Number of subjects: 78
Study 18813732 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 15659542 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin (4 mg/kg every 24 h intravenously for 7-14 days)
Number of subjects: 133
Study 15659542 — intervention group
Group type: COMPARATOR
Intervention: Comparator (vancomycin or semi-synthetic penicillins for 7-14 days)
Number of subjects: 133
Study 12030667 — intervention group
Group type: COMPARATOR
Intervention: Group-based parenting programmes
Number of subjects: 23
Study 10342225 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk product containing 10(7) cfu/ml L. johnsonii La1 (group B)
Number of subjects: 3
Study 10342225 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk product containing 10(6) cfu/ml L. johnsonii La1 (group C)
Number of subjects: 3
Study 10342225 — intervention group
Group type: COMPARATOR
Intervention: Fermented milk product fermented by Streptococcus thermophilus (group A)
Number of subjects: 3
Study 7875642 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone (50, 100, and 200 mg)
Number of subjects: 32
Study 7875642 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxy‐nefazodone
Number of subjects: 32
Study 7875642 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone and Hydroxy‐nefazodone
Number of subjects: 32
Study 7875642 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 32
Study 3409855 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleotide-supplemented milk formula (NMF)
Number of subjects: 0
Study 3409855 — intervention group
Group type: COMPARATOR
Intervention: Milk formula (MF)
Number of subjects: 0
Study 3409855 — intervention group
Group type: COMPARATOR
Intervention: Human milk (HM)
Number of subjects: 0
Study 31571270 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐μs pulse width settings
Number of subjects: 16
Study 31571270 — intervention group
Group type: COMPARATOR
Intervention: 60‐μs pulse width settings
Number of subjects: 16
Study 29307527 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic therapy followed by management as usual
Number of subjects: 684
Study 29307527 — intervention group
Group type: COMPARATOR
Intervention: Management as usual
Number of subjects: 684
Study 28856511 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA)
Number of subjects: 80
Study 28856511 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal morphine (ITM)
Number of subjects: 80
Study 23596055 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly carboplatin and paclitaxel with radiation
Number of subjects: 70
Study 23596055 — intervention group
Group type: COMPARATOR
Intervention: High-dose cisplatin and radiation
Number of subjects: 70
Study 23596055 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly chemotherapy and radiation
Number of subjects: 70
Study 23596055 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy followed by high-dose cisplatin and radiation
Number of subjects: 70
Study 22840826 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentoring program
Number of subjects: 158
Study 20386919 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright posture
Number of subjects: 10
Study 20386919 — intervention group
Group type: EXPERIMENTAL
Intervention: 65 degrees R posture
Number of subjects: 10
Study 20386919 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 degrees R posture
Number of subjects: 10
Study 20386919 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine posture
Number of subjects: 10
Study 19102907 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG + stem cell transplantation
Number of subjects: 20
Study 19102907 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 20
Study 15911548 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (3 days)
Number of subjects: 62
Study 15911548 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin (7 days)
Number of subjects: 62
Study 15911548 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin (single dose)
Number of subjects: 62
Study 12644731 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate therapy
Number of subjects: 814
Study 12644731 — intervention group
Group type: COMPARATOR
Intervention: Standard cohort (no pharmacotherapy)
Number of subjects: 814
Study 10596714 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral levofloxacin (300 mg b.i.d.)
Number of subjects: 35
Study 10596714 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ceftazidime (1 g i.v. t.d.)
Number of subjects: 35
Study 8976627 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified composite strength (MCS)
Number of subjects: 0
Study 8976627 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard strength data
Number of subjects: 0
Study 8976627 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric strength measure
Number of subjects: 0
Study 1610994 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 19
Study 1610994 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 19
Study 6742528 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with a commercial standardized aluminum hydroxide‐bound dog dander extract (15 subjects)
Number of subjects: 27
Study 6742528 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections containing histamine (12 subjects)
Number of subjects: 27
Study 31831074 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsychosocial multidisciplinary intervention (physiotherapy, cognitive-behavioral therapy, medication)
Number of subjects: 501
Study 31831074 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical care
Number of subjects: 501
Study 31831074 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsychosocial multidisciplinary intervention
Number of subjects: 501
Study 26954373 — intervention group
Group type: EXPERIMENTAL
Intervention: High social acceptance (parent- and adolescent-rated)
Number of subjects: 93
Study 26954373 — intervention group
Group type: EXPERIMENTAL
Intervention: Low social acceptance (parent- and adolescent-rated)
Number of subjects: 93
Study 26954373 — intervention group
Group type: EXPERIMENTAL
Intervention: Social acceptance
Number of subjects: 93
Study 26954373 — intervention group
Group type: EXPERIMENTAL
Intervention: Inattention
Number of subjects: 93
Study 26833250 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention units (team-based interprofessional care)
Number of subjects: 1384
Study 25561122 — intervention group
Group type: COMPARATOR
Intervention: Oat bran shake (OB)
Number of subjects: 22
Study 25561122 — intervention group
Group type: COMPARATOR
Intervention: Flaxseed shake (F)
Number of subjects: 22
Study 25561122 — intervention group
Group type: COMPARATOR
Intervention: Unripe banana flour shake (UB)
Number of subjects: 22
Study 25561122 — intervention group
Group type: COMPARATOR
Intervention: White bean extract shake (WB)
Number of subjects: 22
Study 25561122 — intervention group
Group type: EXPERIMENTAL
Intervention: Control shake (C)
Number of subjects: 22
Study 22828460 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthin (Asx)
Number of subjects: 32
Study 22828460 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 32
Study 21060068 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 4162
Study 21060068 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 80 mg
Number of subjects: 4162
Study 17626140 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 3350 plus electrolytes (PEG+E)
Number of subjects: 51
Study 17626140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 16302897 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing system (n = 103)
Number of subjects: 184
Study 16302897 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular pacing system (n = 81)
Number of subjects: 184
Study 12479191 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 1.0 mg x kg(‐1) and Nicardipine 30 microg x kg(‐1)
Number of subjects: 100
Study 12479191 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 100
Study 9452149 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 32
Study 9452149 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 32
Study 9452149 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (DLCO increased by +23%)
Number of subjects: 32
Study 9452149 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (DLCO decreased by -17.5%)
Number of subjects: 32
Study 9452149 — intervention group
Group type: COMPARATOR
Intervention: Group 1 vs Group 2
Number of subjects: 32
Study 9452149 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of DLCO changes
Number of subjects: 32
Study 8545860 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA) 1‐2 mg/kg/day
Number of subjects: 47
Study 8545860 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil 2 gm/day (MMF2)
Number of subjects: 47
Study 8545860 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil 3 gm/day (MMF3)
Number of subjects: 47
Study 2040324 — intervention group
Group type: EXPERIMENTAL
Intervention: sotalol
Number of subjects: 67
Study 2040324 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 67
Study 7471966 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor XIII level measurement before and after surgery
Number of subjects: 76
Study 7471966 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentration measurement before and after surgery
Number of subjects: 76
Study 31917386 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat Hepatectomy
Number of subjects: 0
Study 31917386 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous Radiofrequency Ablation
Number of subjects: 0
Study 31465859 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise condition of 150 min/week (N = 213)
Number of subjects: 639
Study 31465859 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise condition at 225 min/week (N = 213)
Number of subjects: 639
Study 31465859 — intervention group
Group type: COMPARATOR
Intervention: Light intensity stretching-and-toning control condition for 150 min/week (N = 213)
Number of subjects: 639
Study 28561987 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol and Foleys catheter
Number of subjects: 335
Study 28561987 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol alone
Number of subjects: 335
Study 25513788 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 80
Study 25513788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 24773418 — intervention group
Group type: EXPERIMENTAL
Intervention: Television food advertisements
Number of subjects: 284
Study 22247406 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip flexion assist orthosis
Number of subjects: 62
Study 20874499 — intervention group
Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03%
Number of subjects: 195
Study 20874499 — intervention group
Group type: COMPARATOR
Intervention: brimonidine 0.2%
Number of subjects: 195
Study 17426465 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg, n=30)
Number of subjects: 60
Study 17426465 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=30)
Number of subjects: 60
Study 16386089 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 39
Study 16386089 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 39
Study 12108888 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment modifications including extent of staging work-up, radiation field size and dose, optimal chemotherapy regimen, number of cycles of chemotherapy, limited- vs extended-field radiation therapy and dose.
Number of subjects: 0
Study 12108888 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone in early-stage patients.
Number of subjects: 0
Study 9796090 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose estradiol-releasing vaginal ring
Number of subjects: 84
Study 9796090 — intervention group
Group type: COMPARATOR
Intervention: Placebo ring
Number of subjects: 84
Study 7637171 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-ECG transmission
Number of subjects: 59
Study 2523663 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg twice daily
Number of subjects: 489
Study 2523663 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (various doses)
Number of subjects: 489
Study 2523663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 489
Study 2523663 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (doses above 10 mg per day)
Number of subjects: 489
Study 1071960 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic
Number of subjects: 19
Study 1071960 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 19
Study 1071960 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of diuretic and propranolol
Number of subjects: 19
Study 1071960 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 19
Study 31208826 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating brackets (SLB)
Number of subjects: 88
Study 31208826 — intervention group
Group type: COMPARATOR
Intervention: Conventional brackets (CB)
Number of subjects: 88
Study 31860171 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP indication
Number of subjects: 105
Study 31860171 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP indication in trial sites
Number of subjects: 105
Study 31860171 — intervention group
Group type: COMPARATOR
Intervention: Non-study MSAs
Number of subjects: 105
Study 29135431 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention
Number of subjects: 19
Study 29135431 — intervention group
Group type: COMPARATOR
Intervention: Standard care intervention
Number of subjects: 19
Study 25661906 — intervention group
Group type: EXPERIMENTAL
Intervention: aPRP
Number of subjects: 80
Study 25661906 — intervention group
Group type: COMPARATOR
Intervention: No aPRP (Control)
Number of subjects: 80
Study 24029572 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber laryngeal mask airway (LMA)
Number of subjects: 300
Study 24029572 — intervention group
Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 300
Study 24029572 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 300
Study 24029572 — intervention group
Group type: COMPARATOR
Intervention: All groups (LMA, tracheal intubation, spinal anesthesia)
Number of subjects: 300
Study 22261988 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-session preventive group intervention
Number of subjects: 1719
Study 22261988 — intervention group
Group type: COMPARATOR
Intervention: 4 sessions providing the same information given in usual care (Control)
Number of subjects: 1719
Study 19736165 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (aspirin, thienopyridine, cilostazol)
Number of subjects: 2809
Study 17762804 — intervention group
Group type: EXPERIMENTAL
Intervention: Back support plus education
Number of subjects: 433
Study 17762804 — intervention group
Group type: COMPARATOR
Intervention: Education alone
Number of subjects: 433
Study 15302719 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive physician seminar
Number of subjects: 637
Study 15302719 — intervention group
Group type: COMPARATOR
Intervention: No educational programs (control)
Number of subjects: 637
Study 11749988 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management
Number of subjects: 34
Study 11749988 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 34
Study 9338535 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP System FEIA for egg
Number of subjects: 196
Study 9338535 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP System FEIA for milk
Number of subjects: 196
Study 9338535 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP System FEIA for peanut
Number of subjects: 196
Study 9338535 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP System FEIA for fish
Number of subjects: 196
Study 9338535 — intervention group
Group type: COMPARATOR
Intervention: Skin prick tests
Number of subjects: 196
Study 9338535 — intervention group
Group type: COMPARATOR
Intervention: DBPCFCs
Number of subjects: 196
Study 7584277 — intervention group
Group type: EXPERIMENTAL
Intervention: Faces with two names (e.g., actors playing nameable characters)
Number of subjects: 0
Study 7584277 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental setting testing the frequency effect
Number of subjects: 0
Study 3425862 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-aspartyl-glutamate (NAAGA)
Number of subjects: 18
Study 3425862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30813625 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate (HC) meal
Number of subjects: 46
Study 30813625 — intervention group
Group type: COMPARATOR
Intervention: High-fat (HF) meal
Number of subjects: 46
Study 30813625 — intervention group
Group type: COMPARATOR
Intervention: Normo-carbohydrate (NC) meal
Number of subjects: 46
Study 29685815 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab (900 mg)
Number of subjects: 34
Study 29685815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 29685815 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 34
Study 26707858 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time radiation monitoring
Number of subjects: 505
Study 26707858 — intervention group
Group type: COMPARATOR
Intervention: No real-time radiation monitoring (Control)
Number of subjects: 505
Study 26707858 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a radioabsorbent drape
Number of subjects: 505
Study 26707858 — intervention group
Group type: COMPARATOR
Intervention: No use of a radioabsorbent drape (Control)
Number of subjects: 505
Study 26707858 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic total occlusion (CTO) intervention
Number of subjects: 505
Study 26707858 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 505
Study 26707858 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index >30 kg/m2
Number of subjects: 505
Study 26707858 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior MI
Number of subjects: 505
Study 26707858 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior cerebrovascular disease
Number of subjects: 505
Study 26707858 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 505
Study 26707858 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior coronary artery bypass graft surgery
Number of subjects: 505
Study 25023799 — intervention group
Group type: EXPERIMENTAL
Intervention: DRC-based diet with 0% WDGS and 84 mg/steer ZH
Number of subjects: 438
Study 25023799 — intervention group
Group type: COMPARATOR
Intervention: DRC-based diet with 0% WDGS and no ZH
Number of subjects: 438
Study 25023799 — intervention group
Group type: EXPERIMENTAL
Intervention: DRC-based diet with 30% WDGS and 84 mg/steer of ZH
Number of subjects: 438
Study 25023799 — intervention group
Group type: COMPARATOR
Intervention: DRC-based diet with 30% WDGS and no ZH
Number of subjects: 438
Study 21925806 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (1mg BID)
Number of subjects: 37
Study 21925806 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 37
Study 21925806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 20865877 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 70
Study 20865877 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 70
Study 20865877 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion
Number of subjects: 70
Study 20865877 — intervention group
Group type: COMPARATOR
Intervention: Control (none specified)
Number of subjects: 70
Study 18261965 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg (BMI ≤50 kg/m2) or 60 mg (BMI >50 kg/m2) every 12 hours during hospitalization and once daily for 10 days after discharge
Number of subjects: 223
Study 16098296 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty with abciximab
Number of subjects: 1975
Study 16098296 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting with abciximab
Number of subjects: 1975
Study 16098296 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombocytopenia
Number of subjects: 1975
Study 12112403 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 14
Study 12112403 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 14
Study 10995136 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous propofol administration
Number of subjects: 50
Study 10995136 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane 1%
Number of subjects: 50
Study 7488301 — intervention group
Group type: EXPERIMENTAL
Intervention: Retard capsule containing 20 mg PE hydrochloride and 4 mg CA maleate
Number of subjects: 20
Study 7488301 — intervention group
Group type: COMPARATOR
Intervention: Aqueous solution of the same active principles
Number of subjects: 20
Study 7488301 — intervention group
Group type: EXPERIMENTAL
Intervention: Retard capsule under repeated dosing conditions (one capsule b.i.d. during 4 days)
Number of subjects: 20